Skip to main content

Table 1 Baseline characteristic

From: The machine learning methods to analyze the using strategy of antiplatelet drugs in ischaemic stroke patients with gastrointestinal haemorrhage

variables

Stopped group

(N = 176)

Reduced group

(N = 92)

P*

Age, years

67.45(13.15)

66.13(14.16)

0.447

Female, %

71(40.3)

37(40.2)

0.545

Admission NIHSS score

11.55(7.01)

12.78(7.60)

0.184

Endovascular Treatment, %

61(34.7)

26(28.3)

0.178

Taking aspirin, %

96(54.5)

54(59.7)

0.483

Statins In Hospital, %

168(95.5)

88(95.7)

0.949

Length of stay, days, mean (SD)

14.34 (2.21)

18.23 (1.92)

0.067

Systolic Blood Pressure, mmHg

146.96(25.06)

144.15(26.60)

0.395

Diastolic Blood Pressure, mmHg

83.40(16.01)

83.11(17.67)

0.859

History of Smoking, %

67(38.1)

35(38.0)

0.402

History of Drinking, %

34(19.3)

14(15.2)

0.387

History of Stroke, %

17(9.7)

7(7.6)

0.377

History of Hypertension, %

79(44.9)

49(53.3)

0.120

History of Diabetes Mellitus, %

29(16.5)

13(14.1)

0.377

History of CHD, %

20(11.4)

13(14.1)

0.628

History of Antiplatelet Drug, %

20 (11.4)

10(10.9)

0.539

History of Statins, %

14(8.0)

8(8.7)

0.914

History of Antihypertensive, %

58(33.0)

40(43.5)

0.021

History of Hypoglycaemic, %

20(11.4)

12(13.0)

0.526

Platelet, mmol/l

180.30(60.22)

174.80(56.80)

0.470

INR

0.98(0.09)

1.01(0.14)

0.101

ALT, mmol/l

22.82(14.02)

23.07(15.37)

0.895

Creatinine, mmol/l

79.22(26.47)

78.59(22.65)

0.846

Glucose, mmol/l

7.99(2.68)

8.18(3.56)

0.614

Triglyceride, mmol/l

1.68(1.50)

1.69(1.18)

0.960

Total cholesterol, mmol/l

4.36(1.00)

4.34(1.11)

0.907

HDL-C, mmol/l

1.28(0.40)

1.24(0.33)

0.422

LDL-C, mmol/l

2.58(0.84)

2.62(0.92)

0.733

  1. P* was calculated by ANOVA, Chi-square test as appropriate. CHD Coronary Heart Disease, INR international normalized ratio, ALT glutamic-pyruvic transaminase, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein